Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04111510 · ClinicalTrials.gov registry record · Phase 2
Autologous Tumor Infiltrating Lymphocytes in Patients With Pretreated Metastatic Triple Negative Breast Cancer
A Phase 2 study, sponsored by Yale University.
- Completed
- Registry status
- Phase 2
- Development phase
- 6
- Enrollment target
NCT04111510 is a Phase 2 study that has completed, run by Yale University. The registered enrollment target is 6 participants.
The verdict
NCT04111510, a Phase 2 study, has completed, sponsored by Yale University.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 6 participants
- Enrollment target
Study Summary
This study will investigate the safety and efficacy of TIL therapy in patients with metastatic TNBC who have progressed on at least one and no more than three prior systemic anticancer therapies.
Interventions
- DRUG Tumor infiltrating lymphocytes (TIL) LN-145
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2019-12-23 |
| Est. Completion | 2023-05-11 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04111510
The ClinicalTrials.gov registry entry for NCT04111510 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 6 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Yale University, which has 1,492 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Tumor infiltrating lymphocytes (TIL) LN-145 is the first listed.
NCT04111510 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04111510 about?
NCT04111510 is a clinical study titled "Autologous Tumor Infiltrating Lymphocytes in Patients With Pretreated Metastatic Triple Negative Breast Cancer". This study will investigate the safety and efficacy of TIL therapy in patients with metastatic TNBC who have progressed on at least one and no more than three prior systemic anticancer therapies.
What is the current status of trial NCT04111510?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 6 participants. The study started on 2019-12-23. Estimated completion is 2023-05-11.
What interventions are being tested in trial NCT04111510?
The interventions under investigation include: Tumor infiltrating lymphocytes (TIL) LN-145 (DRUG).
Who is sponsoring clinical trial NCT04111510?
This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.